Manifold MarketsGeen KYCGeverifieerde afwikkelingsgegevensRedelijk gekalibreerdHuidige gemeenschapsvoorspellingNee 56.3%
Voorspellers
3
Vraagtype
binary
Methodologie
Play-money forecasting platform
Brontype
Voorspelling
Marktdata
Bijgewerkt 20 uur geleden
Verouderd23 jun 26, 23:28 UTC31 dec 26, 23:59 UTC
Trends
Regels
Background: ChangXin Memory Technologies (CXMT) is China's leading DRAM maker and the country's main hope for a domestic HBM supply, which most analysts consider the binding constraint on China's AI accelerator buildout — more than logic-die capacity.
- CXMT has targeted end-of-2026 HBM3 mass production, but as of April 2026, multiple reports described it as still in sampling/testing with the timeline slipping.
- YES if, on or before Dec 31, 2026, at least one credible source (SemiAnalysis, TrendForce, TechInsights, Digitimes, Reuters, Bloomberg, Nikkei, ChosunBiz, or equivalent industry/financial outlet) reports that CXMT has entered mass/volume production of HBM3 — meaning sustained commercial output, with product shipping to or qualified by at least one customer.
- NO if credible reporting indicates CXMT remains at sampling, pilot, qualification, or risk-production stage; if mass production has slipped to 2027 or later; or if the only support is a CXMT roadmap/target statement or press release without third-party confirmation of actual volume output.
- Tiebreaks: (1) Samples, engineering runs, and "risk production" do not count — the bar is commercial volume.
- (2) A company announcement alone does not resolve YES; independent confirmation is required.
